Annoroad and Illumina to Co-Develop NGS Diagnostic System
News Jun 11, 2015
Annoroad and Illumina, Inc. have announced that they have entered into an agreement to jointly develop advanced clinical applications for reproductive health based on next-generation sequencing (NGS) technology. The collaboration signals the increasing importance of genomic applications to improve healthcare in China.
In recent years, NGS technology has evolved rapidly and is regarded as an essential factor for enabling precision medicine. The collaboration between Annoroad and Illumina will focus on providing the most advanced and integrated sequencing solutions to the clinical market. In particular, the two companies will work together to develop a user-friendly, prenatal DNA diagnostic system for the Chinese market.
The collaboration will bring together technology from Illumina sequencers with Annoroad’s advanced clinical application development capabilities. As part of the agreement, Annoroad will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.
"We have been working to promote the clinical application of genomic technology in China. Non-invasive prenatal testing is used widely in the reproductive health arena, and we hope to promote it as a standard practice in hospitals. As one of the first national clinical pilot sites for NGS appointed by the National Health and Family Planning Commission (formerly the Ministry of Health), Annoroad is now very pleased to partner with Illumina, the global leader in sequencing and array technologies. Cooperation between our two companies will provide additional high-quality diagnostic solutions in the field of reproductive health," said Junbin Liang, Annoroad Founder and Chief Executive Officer.
“Illumina is very excited to collaborate with Annoroad to increase access to reproductive health solutions in China,” said Tristan Orpin, Senior Vice President and General Manager of Illumina’s Reproductive and Genetic Health business. “We are committed to partnering with Chinese companies who share our vision of improving human health by unlocking the power of the genome.”
In a new paper,an international team of researchers has discovered that the gene FT — the primary driver of the transition to flowering in plants each spring — does something unexpected in Arabidopsis thaliana plants grown in natural environments, with implications for the artificial growing conditions scientists commonly used in the labREAD MORE